| __timestamp | HUTCHMED (China) Limited | Ultragenyx Pharmaceutical Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 33472000 | 45967000 |
| Thursday, January 1, 2015 | 47368000 | 114737000 |
| Friday, January 1, 2016 | 66871000 | 183204000 |
| Sunday, January 1, 2017 | 50675000 | 231644000 |
| Monday, January 1, 2018 | 78821000 | 293998000 |
| Tuesday, January 1, 2019 | 91944000 | 357355000 |
| Wednesday, January 1, 2020 | 111234000 | 412084000 |
| Friday, January 1, 2021 | 207447000 | 497153000 |
| Saturday, January 1, 2022 | 267587000 | 705789000 |
| Sunday, January 1, 2023 | 303055000 | 648449000 |
Unleashing the power of data
In the ever-evolving landscape of biopharmaceuticals, research and development (R&D) expenses are a critical indicator of a company's commitment to innovation. Over the past decade, Ultragenyx Pharmaceutical Inc. and HUTCHMED (China) Limited have demonstrated significant investment in R&D, reflecting their dedication to advancing medical science.
From 2014 to 2023, Ultragenyx's R&D expenses surged by over 1,300%, peaking in 2022 with a remarkable 705 million USD. This growth underscores their aggressive pursuit of groundbreaking therapies. Meanwhile, HUTCHMED's R&D spending increased by approximately 800%, reaching 303 million USD in 2023. This steady rise highlights their strategic focus on expanding their research capabilities.
These trends not only showcase the companies' growth trajectories but also emphasize the broader industry's shift towards more substantial R&D investments, crucial for fostering innovation and addressing unmet medical needs.
Analyzing R&D Budgets: Amgen Inc. vs HUTCHMED (China) Limited
Takeda Pharmaceutical Company Limited or HUTCHMED (China) Limited: Who Invests More in Innovation?
Biogen Inc. or HUTCHMED (China) Limited: Who Invests More in Innovation?
Comparing Innovation Spending: United Therapeutics Corporation and Ultragenyx Pharmaceutical Inc.
R&D Spending Showdown: BioMarin Pharmaceutical Inc. vs Ultragenyx Pharmaceutical Inc.
Comparing Innovation Spending: Madrigal Pharmaceuticals, Inc. and HUTCHMED (China) Limited
Research and Development Investment: Grifols, S.A. vs HUTCHMED (China) Limited
R&D Spending Showdown: Ultragenyx Pharmaceutical Inc. vs MorphoSys AG
Who Prioritizes Innovation? R&D Spending Compared for Ultragenyx Pharmaceutical Inc. and Amphastar Pharmaceuticals, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Ultragenyx Pharmaceutical Inc. and MannKind Corporation
Research and Development Expenses Breakdown: Viking Therapeutics, Inc. vs HUTCHMED (China) Limited
Analyzing R&D Budgets: HUTCHMED (China) Limited vs Geron Corporation